Yutao Guo1,2, Agnieszka Kotalczyk2,3, Jacopo F Imberti2,4, Yutang Wang5, Gregory Y H Lip1,2,6. 1. Department of Pulmonary Vessel and Thrombotic Disease, Sixth Medical Centre, Chinese PLA General Hospital, Beijing, 100142, China. 2. Liverpool Centre for Cardiovascular Science, University of Liverpool and Liverpool Heart & Chest Hospital, Liverpool, United Kingdom. 3. Department of Cardiology, Congenital Heart Diseases and Electrotherapy, Medical University of Silesia, Silesian Centre for Heart Diseases, Zabrze, Poland. 4. Cardiology Division, Department of Biomedical, Metabolic and Neural Sciences, University of Modena and Reggio Emilia, Policlinico di Modena, Modena, Italy. 5. Department of Cardiology, Second Medical Centre, Chinese PLA General Hospital, Beijing, 100853, China. 6. Aalborg Thrombosis Research Unit, Department of Clinical Medicine, Aalborg University, Aalborg, Denmark.
Abstract
BACKGROUND: Adherence to guideline-directed oral anticoagulation (OAC) in patients with atrial fibrillation (AF) improves outcomes, but limited data are available from China. AIM: To evaluate the adherence to guideline-directed anticoagulation and its impact on clinical outcomes in a high-risk cohort of elderly Chinese patients. METHODS: The Optimal Thromboprophylaxis in Elderly Chinese Patients with Atrial Fibrillation (ChiOTEAF) registry is a prospective, multicenter study conducted from October 2014 to December 2018. Endpoints of interest were all-cause death, thromboembolic (TE) events and major bleedings in patients with a guideline-directed indication for OACs (CHA2DS2VASc ≥1 if male or ≥2 if female). RESULTS: The eligible cohort consisted of 5742 patients, of whom 2567 (44.7%) patients were treated with an OAC. Seven independent predictors of OAC undertreatment were identified: age (OR: 1.04; 95%CI 1.03-1.05, P < 0.001), first diagnosed AF (OR: 1.71; 95%CI 1.44-2.03, P < 0.001), chronic kidney disease (OR: 1.67; 95%CI 1.36-2.06, P < 0.001), liver disease (OR: 1.69; 95%CI 1.19-2.41, P = 0.003), dementia (OR: 1.67; 95%CI 1.06-2.64, P = 0.026), prior extracranial bleeding (OR: 1.89; 95%CI 1.35-2.64, P < 0.001), and the use of antiplatelet drug (OR: 6.97; 95%CI 5.89-8.23, P < 0.001). On multivariate analysis, OAC undertreatment was significantly associated with a higher risk all-cause death (OR: 3.79; 95%CI: 2.61-5.53; P < 0.001) and TE events (OR: 2.28; 95%CI: 1.39-3.72; P = 0.001), and a similar risk of major bleeding as compared to guideline-directed OAC therapy. CONCLUSIONS: Only 44.7% of all eligible patients were prescribed OAC in accordance with guideline recommendations. The independent predictors for OAC undertreatment were age, first diagnosed AF, chronic kidney disease, chronic obstructive pulmonary disease, prior extracranial bleeding, and the use of the antiplatelet drugs. Guideline-adherent thromboprophylaxis was safe and may be associated with improved survival and less TE among elderly Chinese patients with AF.
BACKGROUND: Adherence to guideline-directed oral anticoagulation (OAC) in patients with atrial fibrillation (AF) improves outcomes, but limited data are available from China. AIM: To evaluate the adherence to guideline-directed anticoagulation and its impact on clinical outcomes in a high-risk cohort of elderly Chinese patients. METHODS: The Optimal Thromboprophylaxis in Elderly Chinese Patients with Atrial Fibrillation (ChiOTEAF) registry is a prospective, multicenter study conducted from October 2014 to December 2018. Endpoints of interest were all-cause death, thromboembolic (TE) events and major bleedings in patients with a guideline-directed indication for OACs (CHA2DS2VASc ≥1 if male or ≥2 if female). RESULTS: The eligible cohort consisted of 5742 patients, of whom 2567 (44.7%) patients were treated with an OAC. Seven independent predictors of OAC undertreatment were identified: age (OR: 1.04; 95%CI 1.03-1.05, P < 0.001), first diagnosed AF (OR: 1.71; 95%CI 1.44-2.03, P < 0.001), chronic kidney disease (OR: 1.67; 95%CI 1.36-2.06, P < 0.001), liver disease (OR: 1.69; 95%CI 1.19-2.41, P = 0.003), dementia (OR: 1.67; 95%CI 1.06-2.64, P = 0.026), prior extracranial bleeding (OR: 1.89; 95%CI 1.35-2.64, P < 0.001), and the use of antiplatelet drug (OR: 6.97; 95%CI 5.89-8.23, P < 0.001). On multivariate analysis, OAC undertreatment was significantly associated with a higher risk all-cause death (OR: 3.79; 95%CI: 2.61-5.53; P < 0.001) and TE events (OR: 2.28; 95%CI: 1.39-3.72; P = 0.001), and a similar risk of major bleeding as compared to guideline-directed OAC therapy. CONCLUSIONS: Only 44.7% of all eligible patients were prescribed OAC in accordance with guideline recommendations. The independent predictors for OAC undertreatment were age, first diagnosed AF, chronic kidney disease, chronic obstructive pulmonary disease, prior extracranial bleeding, and the use of the antiplatelet drugs. Guideline-adherent thromboprophylaxis was safe and may be associated with improved survival and less TE among elderly Chinese patients with AF.
Authors: Valentina Bayer; Agnieszka Kotalczyk; Bory Kea; Christine Teutsch; Peter Larsen; Dana Button; Menno V Huisman; Gregory Y H Lip; Brian Olshansky Journal: J Am Heart Assoc Date: 2022-03-04 Impact factor: 6.106